Introduction
DOTATATE PET-CT (Gallium-68 DOTATATE Positron Emission Tomography – Computed Tomography) is a highly specialized molecular imaging test used primarily for the diagnosis, staging, and follow-up of neuroendocrine tumors (NETs).
It targets somatostatin receptors, which are commonly overexpressed on the surface of many neuroendocrine tumor cells.
By combining receptor-specific functional imaging with detailed anatomical CT images, DOTATATE PET-CT provides exceptional sensitivity and accuracy in detecting neuroendocrine disease.
It plays a critical role in determining disease extent, selecting appropriate therapies, and monitoring treatment response.
Türkiye is a trusted destination for advanced nuclear medicine imaging, offering modern DOTATATE PET-CT technology, experienced specialists, and integrated neuroendocrine oncology care.
Averia Health supports international patients through ethical, structured, and fully coordinated DOTATATE PET-CT services focused on diagnostic precision and clinical clarity.
Why Choose Türkiye for DOTATATE PET-CT
Türkiye is internationally recognized for high-quality neuroendocrine tumor imaging because of:
- Advanced PET-CT scanners optimized for receptor-based imaging
- Availability of Ga-68 DOTATATE radiotracers
- Experienced nuclear medicine physicians with NET expertise
- Strict radiation safety and quality assurance standards
- Multidisciplinary collaboration with oncology, endocrinology, and surgery teams
- Internationally accredited hospitals
Türkiye combines cutting-edge imaging technology with specialized oncologic expertise.
Why Choose Averia Health
Averia Health provides comprehensive coordination for DOTATATE PET-CT scans:
- Pre-arrival review of medical history, pathology, and prior imaging
- Referral to accredited nuclear medicine centers experienced in NET imaging
- Clear explanation of scan purpose and preparation requirements
- Coordination with oncology, endocrinology, or surgical teams
- Professional interpreter services
- 24/7 patient support during your visit
- Timely reporting and international follow-up coordination
Our approach prioritizes accuracy, transparency, and patient reassurance.
Conditions Evaluated with DOTATATE PET-CT
DOTATATE PET-CT is primarily used for:
- Neuroendocrine tumors of the gastrointestinal tract
- Pancreatic neuroendocrine tumors (pNETs)
- Neuroendocrine tumors of unknown primary origin
- Lung neuroendocrine tumors
- Metastatic neuroendocrine disease
- Assessment of somatostatin receptor expression
- Treatment planning for peptide receptor radionuclide therapy (PRRT)
It is particularly valuable when conventional imaging is inconclusive.
Types of DOTATATE PET-CT Applications
Initial NET Staging
Determines the full extent of disease at diagnosis.
Detection of Primary Tumor
Identifies the origin of metastatic neuroendocrine tumors.
Disease Restaging and Follow-Up
Evaluates progression or response to treatment.
PRRT Eligibility Assessment
Confirms somatostatin receptor expression before targeted radionuclide therapy.
The scan protocol is tailored to each patient’s clinical scenario.
Diagnostic Evaluation Before DOTATATE PET-CT
Preparation and evaluation may include:
- Review of pathology confirming neuroendocrine tumor
- Review of prior imaging (CT, MRI, FDG PET-CT if available)
- Medication review, including somatostatin analog therapy
- Hydration instructions before the scan
- Assessment for pregnancy or breastfeeding when applicable
Proper preparation ensures optimal image quality and diagnostic accuracy.
DOTATATE PET-CT Scan Journey in Türkiye
- Pre-Arrival Case Review
Medical records and imaging indications are reviewed in advance. - Nuclear Medicine Consultation
The procedure, tracer mechanism, and expectations are explained clearly. - DOTATATE Tracer Administration
A small, targeted radiotracer is administered safely. - PET-CT Imaging
Whole-body imaging is performed using advanced hybrid PET-CT systems. - Image Interpretation
Results are analyzed by experienced nuclear medicine specialists. - Results & Care Coordination
Findings are shared with your treating physician to guide next steps.
Expected Results & Benefits
- Highly sensitive detection of neuroendocrine tumors
- Accurate staging and localization of disease
- Improved treatment selection and planning
- Assessment of suitability for targeted therapies such as PRRT
- Reduced uncertainty compared to conventional imaging
DOTATATE PET-CT is considered the gold standard imaging modality for many NETs.
Risks & Considerations
DOTATATE PET-CT is safe and well established. Considerations include:
- Exposure to a low level of radiation
- Temporary discomfort from tracer injection
- Need to follow preparation instructions carefully
Radiation exposure is minimized and justified by the diagnostic benefit.
What’s Included in Your Medical Visit
- DOTATATE PET-CT scan appointment
- Nuclear medicine consultation
- Ga-68 DOTATATE tracer administration
- PET-CT imaging and expert interpretation
- Written diagnostic report
- Coordination with oncology or endocrinology teams
- Interpreter services
- Patient support and follow-up coordination
Averia Health ensures ethical, precise, and patient-centered neuroendocrine imaging care.
Frequently Asked Questions
How is DOTATATE PET-CT different from FDG PET-CT?
DOTATATE targets somatostatin receptors and is more specific for neuroendocrine tumors.
Can DOTATATE PET-CT detect small lesions?
Yes. It is highly sensitive, even for small or early-stage NET lesions.
Is DOTATATE PET-CT safe?
Yes. Radiation exposure is controlled within accepted medical standards.
Do all NET patients need DOTATATE PET-CT?
It is recommended based on tumor type, grade, and clinical needs.
How quickly will I receive the results?
Results are typically available shortly after expert interpretation.
Ready to Start Your Health Journey?
Gain precise insight into neuroendocrine tumors with advanced DOTATATE PET-CT imaging in Türkiye.
Request a free case review or contact us on WhatsApp to speak with our diagnostic care coordination team.
